B+
Bull case
25%
Probability
Target price
$1.05
+46.5% vs current
CYPH
CypherpunkCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$0.68
-5.1% vs current
B-
Bear case
25%
Probability
Target price
$0.27
-62.3% vs current
AI sentiment snapshot
Latest data as of 2026-06-06
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+38.3
Score
AI commentary
Primary-source evidence is materially better than the prior neutral setup: Nasdaq compliance is closed, the Q1 update confirmed further ZEC accumulation plus a $5 million ZODL investment, and Leap's program gained FDA Fast Track status. Even so, this is still a low-coverage hybrid story with no analyst revisions or consensus-target confirmation, so conviction stays capped and the right frame is monitoring rather than a clean directional long thesis [#8-K-2026-05-26] [#SEC-8K-2026-05-14] [#10-K-2026-03-16].
RankAlpha Sentiment Codex - 2026-06-06
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-14eventQ1 2026 update reinforced the ZEC treasury pivot and biotech option valueHigh impact
The May 14, 2026 8-K press release said Cypherpunk had increased treasury holdings to 314,185.70 ZEC, invested $5 million into ZODL, launched an investor dashboard, and disclosed FDA Fast Track designation for sirexatamab in DKK1-high metastatic colorectal cancer [#SEC-8K-2026-05-14].
2026-05-26catalystNasdaq compliance overhang closedMedium impact
On May 21, 2026 the company received Nasdaq's notice that it had regained compliance and the matter was closed, removing a technical listing overhang [#8-K-2026-05-26]. This is mainly a sentiment cleanup catalyst rather than a change in operating fundamentals.
2026-12-31catalystProving the hybrid treasury/biotech model can fund itselfHigh impact
The 2025 10-K frames Cypherpunk as a privacy-technology company with ZEC as its primary digital asset while Leap still advances oncology work, so the long-horizon question is whether treasury gains, partnerships, or financing discipline can support the biotech program without heavy dilution [#10-K-2026-03-16].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-06 • Updated nightlySource: Internal modelMethodology